Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Federal Trade Commission
Merck
Medtronic
Julphar
Healthtrust
Moodys
Chinese Patent Office
Express Scripts

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,951,797

« Back to Dashboard

Which drugs does patent 7,951,797 protect, and when does it expire?

Patent 7,951,797 protects BELSOMRA and is included in one NDA.

This patent has fifty-one patent family members in thirty-five countries.
Summary for Patent: 7,951,797
Title:Substituted diazepan orexin receptor antagonists
Abstract: The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Inventor(s): Breslin; Michael J. (Drexel Hill, PA), Coleman; Paul J. (Wallingford, PA), Cox; Christopher D. (Harleysville, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:11/998,812
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,951,797

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-001 Aug 13, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF INSOMNIA ➤ Sign Up
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-002 Aug 13, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF INSOMNIA ➤ Sign Up
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-003 Aug 13, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF INSOMNIA ➤ Sign Up
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-004 Aug 13, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF INSOMNIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
Healthtrust
US Department of Justice
Teva
Fuji
Cerilliant
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.